REVIEW
Annals of Nuclear Medicine Vol. 17, No. 3, 169–179, 2003
Myocardial viability assessment using nuclear imaging
Ichiro MATSUNARI,* Junichi TAKI,** Kenichi NAKAJIMA,** Norihisa TONAMI** and Kinichi HISADA*
*The Medical and Pharmacological Research Center Foundation
**Department of Biotracer Medicine, Kanazawa University Graduate School of Medical Sciences
Myocardial assessment continues to be an issue in patients with coronary artery disease and left
ventricular dysfunction. Nuclear imaging has long played an important role in this field. In
particular, PET imaging using 18F-fluorodeoxyglucose is regarded as the metabolic gold standard
of tissue viability, which has been supported by a wide clinical experience. Viability assessment
using SPECT techniques has gained more wide-spread clinical acceptance than PET, because it is
more widely available at lower cost. Moreover, technical advances in SPECT technology such as
gated-SPECT further improve the diagnostic accuracy of the test. However, other imaging
techniques such as dobutamine echocardiography have recently emerged as competitors to nuclear
imaging. It is also important to note that they sometimes may work in a complementary fashion to
nuclear imaging, indicating that an appropriate use of these techniques may significantly improve
their overall accuracy. In keeping these circumstances in mind, further efforts are necessary to
further improve the diagnostic performance of nuclear imaging as a reliable viability test.
Key words:
myocardial viability, PET, SPECT
DESPITE RECENT DEVELOPMENTS in therapeutic options, heart
failure due to coronary artery disease (CAD) continues to
be one of the leading causes of morbidity and mortality in
many countries, including Japan. It is well known that left
ventricular dysfunction is not necessarily an irreversible
process; dysfunctional but viable myocardium has the
potential to recover in function after restoration of myocardial blood flow by either coronary arterial bypass
grafting (CABG) or percutaneous coronary intervention
(PCI), whereas scarred tissue will not recover even after
revascularization.1 Therefore, substantial efforts have
been made to differentiate such potentially reversible, and
hence viable myocardium from scar. Furthermore, it has
also been reported that patient selection based on the
presence and extent of tissue viability identifies patients
who are at low risk for serious perioperative complications associated with CABG.2 Nuclear imaging techniques using either PET3,4 or SPECT5,6 have played a
Received January 27, 2003, revision accepted January 27,
2003.
For reprint contact: Ichiro Matsunari, M.D., The Medical and
Pharmacological Research Center Foundation, Wo 32, Inoyama,
Hakui, Ishikawa 925–0613, JAPAN.
E-mail: matsunari@mprcf.or.jp
Vol. 17, No. 3, 2003
major role in this field. This review describes the basic
physiology of dysfunctional but viable myocardium, and
the current applications of scintigraphic approaches for
the noninvasive characterization of viable and scarred
myocardium.
Pathophysiology Underlying Reversible Dysfunction
It is known that chronically dysfunctional but viable
myocardium may represent hibernation, repetitive stunning, or both. Hibernating myocardium, which was first
described by Rahimtoola,7 represents impaired contractile function coupled with reduced myocardial blood flow
at rest that would recover after restoration of flow. Stunning, on the other hand, represents impaired contractile
function that persists after an ischemic episode despite
restoration of blood flow.8 The differentiation of these
situations is complicated because they may often coexist
in the clinical setting. Furthermore, several clinical studies9,10 have shown that myocardial blood flow in hibernating myocardium is, in fact, not reduced and is often within
the normal or near normal range, suggesting that repetitive stunning rather than hibernation plays a major role in
such chronically dysfunctional but viable myocardium.
Prior studies by Bax et al.11 and Haas et al.12 have suggested that stunned myocardium is likely to show early
Review 169
Table 1 PET tracers used for assessing myocardial viability
18F-FDG
11C-Acetate
13N-Ammonia
15O-Water
82Rb
Mechanism
Imaging procedure
Index of viability
Glucose utilization
Oxidative metabolism
Flow/Metabolic trapping
Flow/Diffusion
Flow/Membrane integrity
Static/Dynamic
Dynamic
Dynamic/Static
Dynamic
Dynamic
Relative uptake
Clearance rate (Kmono)
Flow/Retention
Flow/Perfusable tissue index
Flow/Clearance rate
A
Fig. 1 (A) Short-, sagittal-, and horizontal-axis tomograms of
(upper) and 18F-FDG (lower) PET from a patient
with prior anterior myocardial infarction. Reduced perfusion
associated with preserved FDG uptake (flow-metabolism mismatch) is noted in the antero-septal wall, indicating viable
tissue. (B) Short-axis MRI images from the same patient before
(upper) and after (lower) revascularization by percutaneous
coronary intervention (PCI). As expected from the results of
PET study, a remarkable improvement in regional wall thickening is noted in the antero-septal wall.
13N-ammonia
B
functional recovery after revascularization, whereas hibernating myocardium may take a longer time period to
recover. It is also noteworthy that contractile reserve to
dobutamine infusion is more common in normally perfused (stunned) myocardium than in hypoperfused yet
viable (hibernating) myocardium.13 Additionally, the timing of revascularization after the onset of hibernation may
also be an issue, because progressive cellular degeneration in hibernating myocardium may reduce the chance
for complete structural and functional recovery after
restoration of blood flow.14 Thus, much work still needs
to be done for more comprehensive understanding of
dysfunctional but viable myocardium.
What Is the Gold Standard for Viability Studies?
The choice of gold standard or reference technique for
viability is an issue in most published studies. There have
been many endpoints proposed for viability tests, including metabolic activity measured by 18F-fluorodeoxyglucose (FDG) PET,15 histological examination of biopsied
tissue,16 regional or global functional recovery,3,17–20
170
Ichiro Matsunari, Junichi Taki, Kenichi Nakajima, et al
symptom improvement,21,22 and improved survival.23,24
From a pathophysiological view point, biological signals
by PET or histological examinations should certainly
provide important insights into viability at the cellular or
molecular level. Regional or global functional recovery
after restoration of blood flow is also relevant because this
is directly associated with the definition of stunned or
hibernating myocardium. From a clinical standpoint, on
the other hand, improved survival and symptoms associated with revascularization would be the optimal endpoint
of viability tests, because this is the main goal of revascularization procedures. However, such prognostic information is not always available, because some patients
may drop out during the follow-up period usually for
years. Furthermore, the magnitude of improvement in
symptoms may sometimes be difficult to measure in an
objective manner. Perhaps, the global improvement of
left ventricular function after revascularization is the best
alternative, because this is easy to measure and, is likely
to be associated with improved prognosis.22
Annals of Nuclear Medicine
PET
The clinical utility of PET imaging to identify viable
tissue was first described by Tillisch et al. in the middle
1980’s.3 PET has several technical advantages over SPECT
such as higher counting sensitivity, higher spatial resolution, and routine use of attenuation correction. Until now,
there have been a number of PET studies, most of which
used 18F-FDG as a metabolic marker of viability, in the
literature,2–4,17,19,23,25 and thus PET serves as a metabolic
gold standard for tissue viability. As summarized in Table
1, there are several PET tracers that can be used for
assessing viability.
Metabolic Imaging
18F-FDG
Free fatty acids, glucose, and lactate are the major energy
sources for the heart.26–28 Fatty acids play a major role in
the metabolism of the normoxic heart, whereas glucose
becomes the major substrate for the myocardium under
ischemic conditions.29–31 Therefore, PET imaging using
metabolic tracers such as 18F-FDG enables detection of
metabolic changes at the cellular level associated with
ischemia. As demonstrated in Figure 1, the preserved or
increased glucose utilization, and hence 18F-FDG uptake
in hypoperfused and dysfunctional myocardium (flowmetabolism mismatch) is regarded as a metabolic marker
of cell survival and viability, whereas concordant reduction in both blood flow and 18F-FDG uptake is indicative
of scar. Thus, 18F-FDG PET provides a biological signal
on cellular viability, and is considered to be one of the
most accurate noninvasive techniques to identify viable
tissue, as supported by a number of studies using
PET.2–4,17,19,23,25 From a prognostic viewpoint, it is important to note that the surgical revascularization of hibernating myocardium leads to a decreased mortality rate
compared with medical treatment, whereas revascularization of irreversibly injured myocardium does not prevent
further decline in function.23,25
In clinical practice, 18F-FDG PET is often combined
with flow tracers such as 13N-ammonia to assess myocardial perfusion. Although 18F-FDG PET imaging without
flow tracer may work with reasonable sensitivity and
specificity for detecting viable tissue,32 flow/metabolism
combination would provide more comprehensive information on viability and herein the differentiation of hibernation from stunning.11,12,33
Image interpretation is often performed visually, and
relies on relative regional uptake of 18F-FDG.17 Absolute
quantitation of regional myocardial glucose utilization
using dynamic imaging does not appear to enhance the
diagnostic accuracy of 18F-FDG PET to detect viable
myocardium,34 probably because of high variability in
glucose utilization rates in individual patients. Thus,
relative 18F-FDG uptake is clinically sufficient for this
purpose.
Vol. 17, No. 3, 2003
11C-Acetate
Although 18F-FDG is the most established metabolic
tracer for tissue viability, 18F-FDG may not be suitable for
use in acute myocardial infarction due to inflammatory
cell accumulation in necrotic tissue, which takes up 18FFDG as does viable tissue.35–37 Furthermore, myocardial
18F-FDG uptake is influenced by multiple factors such as
serum glucose, free fatty acids, and insulin levels. Acetate, on the other hand, enters the TCA cycle and its
clearance rate represents cellular oxidative metabolism
independent of the factors affecting 18F-FDG uptake.28
Because preserved oxidative metabolism is essential for
viable cells, its clearance rate can be used as a marker of
viability. Several clinical studies have demonstrated the
utility of 11C-acetate for assessing myocardial viability,38–41 particularly in patients with acute myocardial
infarction. Additionally, a recent study by Hata et al.42
suggests that the use of low-dose dobutamine at the time
of tracer injection further improves the delineation of
reversible and irreversible dysfunction.
A potential disadvantage of 11C-acetate as a viability
tracer, however, is the necessity for dynamic imaging and
calculation of k-mono to differentiate viable from scarred
tissue. Thus, unlike 18F-FDG, a simple visual interpretation of static image is not possible for this tracer. Another
disadvantage is the necessity for an on-site cyclotron for
production of 11C, which has a relatively short physical
half-life of 20 minutes. For these reasons, although the
results as to the utility of this tracer as a viability marker
are promising, 11C-acetate has not gained wide clinical
acceptance at present.
Flow Tracers
Flow measurement using PET also provides information
on cellular viability.43 In particular, unlike SPECT, absolute quantitation of myocardial blood flow is feasible
using PET and tracer kinetic models.44,45 The myocardial
blood flow itself is a marker of viability because viable
tissue requires a blood supply to be alive.43 Additionally,
it is of note that flow is often within the normal or near
normal range in dysfunctional but viable myocardium,9,10
suggesting that the majority of reversible dysfunction
represents repetitive stunning rather than hibernation.
13N-Ammonia
The suitability of 13N-ammonia as a myocardial flow
tracer is established in numerous studies.44,46–52 Uptake of
13N-ammonia depends on both perfusion and metabolic
retention. Therefore, 13N-ammonia retention in the myocardium should reflect tissue viability. This concept was
tested by Kitsiou et al.53 demonstrating that 13N-ammonia
retention rather than absolute myocardial blood flow was
a good marker of cellular viability. Nevertheless, whether
metabolic tracers such as 18F-FDG are necessary for more
accurate delineation of viable tissue remains to be determined by further studies.54
Review 171
Table 2 SPECT tracers used for assessing myocardial viability
Mechanism
201Tl
99mTc-Sestamibi
99mTc-Tetrofosmin
123I-BMIPP
18F-FDG
Flow/Membrane integrity
Flow/Mitochondrial membrane
integrity
Flow/Mitochondrial membrane
integrity
Fatty Acid uptake
Glucose utilization
15O-Water
Unlike 13N-ammonia, 15O-water distributes into the water
spaces of both the myocardium and blood. In theory, 15Owater is considered to be an ideal tracer for measurement
of myocardial blood flow without plateau effect at high
flow rates.45,55 However, methodological complexity related with this tracer (e.g., necessity for subtraction of
blood pool activity) together with very short physical
half-life may cause heterogeneity of flow measurements,
as demonstrated by Nitzsche et al.56 A unique feature of
15O-water PET imaging is that the proportion of the total
anatomical tissue that is capable of rapidly exchanging
water (water perfusable tissue index, PTI) can be used as
a marker of tissue viability.57,58 Although much work
needs to be done before its clinical utility is determined,
this technique appears to provide unique information on
tissue viability.
82Rb
Rubidium-82 is a generator produced positron emitting
tracer to measure myocardial blood flow.59 It is actively
transported into myocardium by sodium-potassium dependent transmembranous ion exchange system in a
manner similar to 201Tl.60 Therefore, its cellular kinetics
represent membrane integrity and hence, viability. Although this concept has not been extensively validated, a
study by vom-Dahl et al.59 showed that tissue half-lives of
82Rb significantly differ between viable and scar tissue.
SPECT
Although PET imaging is an established technique to
distinguish viable from scarred myocardium as described
above, its limited availability and high cost pose limitations for widespread use in clinical practice. Therefore,
substantial efforts have been made to develop SPECT
techniques for viability assessment, which are less expensive and more widely available. As shown in Table 2,
there are several single-photon emitting tracers available
that can be used for assessing myocardial viability.
201Tl
Imaging procedure
Index of viability
Stress-RedistributionReinjection
Rest-Redistribution
Defect reversibility/Relative uptake
Stress-Rest/Rest
Defect reversibility/Relative uptake
Stress-Rest/Rest
Rest
Rest
Defect reversibility/Relative uptake
Reduced uptake compared with flow
Relative uptake
myocardial 201Tl uptake represents both myocardial perfusion and cellular viability. It has been shown that 3–4
hour delayed imaging after stress injection of 201Tl frequently underestimates the presence of viable myocardium within persistent defects as evidenced by metabolic
imaging with 18F-FDG PET.61 Modified 201Tl protocols
such as late redistribution imaging after stress injection62,63 or reinjection technique6,64 have been shown to
enhance the detection of viable myocardium. In particular, reinjection imaging protocol is currently widely used
for this purpose, and has been found to be equivalent to
18F-FDG PET in most circumstances, although viability
in some myocardium may be underestimated by 201Tl as
compared with 18F-FDG PET.64
Rest-redistribution 201Tl imaging is another established
diagnostic protocol for the detection of such viable, but
compromised, myocardium.5 Initial distribution of 201Tl
is considered to reflect myocardial blood flow at rest, and
redistribution 201Tl imaging to reflect myocardial viability rather than mere perfusion. Thus, rest-redistribution
protocol is used when the question being addressed is
solely myocardial viability and not stress induced ischemia. Unlike stress 201Tl, late redistribution imaging
after rest injection may not be necessary for this purpose.65 When rest-redistribution 201Tl imaging is compared with reinjection imaging after stress, both protocols
seem to provide equivalent results as to viability when
regional 201Tl activity on the final image is considered as
a marker of viability.8 However, the presence and extent
of stress induced ischemia gives more relevant information than viability in the majority of CAD patients. Furthermore, a recent study66 has shown that stress induced
reversible defects, which are more commonly seen on
stress imaging than on rest imaging, are highly predictive
of functional recovery after revascularization. Thus, the
use of stress imaging protocol is encouraged whenever
possible.
Images are usually interpreted visually, but quantitation
of regional tracer uptake within the dysfunctional myocardium provides more objective and accurate results as
to tissue viability than visual assessment.67
201Tl
is taken up by myocardial cells by active transport
and is dependent on myocardial blood flow.60 Therefore,
172
Ichiro Matsunari, Junichi Taki, Kenichi Nakajima, et al
Annals of Nuclear Medicine
Fig. 2 Scatter plots showing correlation of quantitative regional
tracer activities between rest-redistribution 201Tl and rest 99mTctetrofosmin imaging. (From Matsunari I, Fujino S, Taki J, et al.
Quantitative rest technetium-99m tetrofosmin imaging in predicting functional recovery after revascularization: comparison
with rest-redistribution thallium-201. J Am Coll Cardiol 1997;
29: 1226–1233. Reproduced with permission of the American
College of Cardiology.)
Fig. 3 123I-BMIPP (left) and 99mTc-tetrofosmin (right) images
from a patient with inferior myocardial infarction. A reduced
123I-BMIPP uptake less than 99mTc-tetrofosmin is noted in the
inferior wall.
as a marker of viability. Furthermore, Udelson et al.18
described the utility of 99mTc-sestamibi for the prediction
of functional recovery after revascularization, which was
comparable to that of 201Tl, in severe CAD patients.
Similar results have been reported for 99mTc-tetrofosmin,
a newer 99mTc-lebeled flow tracer. In a study by Matsunari
et al.,20 99mTc-tetrofosmin uptake also predicted functional recovery as did rest injected 201Tl. These data were
further confirmed by subsequent studies. 74,75 Thus,
quantitation of tracer uptake of 99mTc-sestamibi or 99mTctetrofosmin provides useful information on viability as
does conventional 201Tl.
123I-BMIPP
123I-beta-methyl iodophenyl pentadecanoic acid (BMIPP)
is a fatty acid analog that is not metabolized by betaoxidation,76 and its clinical utility has been extensively
investigated particularly in Japan and Europe. Because
myocardial fatty acid uptake is easily depressed in ischemic but viable myocardium,77 BMIPP imaging in
combination with flow tracer such as 201Tl or 99mTcsestamibi can also detect potentially reversible myocardium. As demonstrated by Taki et al.78 and others,79,80 a
discordant BMIPP uptake less than perfusion tracer uptake (Fig. 3) is considered to be a marker of functional
recovery after revascularization. However, whether
BMIPP imaging combined with perfusion tracer has any
advantage over perfusion tracer alone for the detection of
compromised but viable myocardium remains to be elucidated in a large patient cohort, although initial results
are promising.81
18F-FDG
SPECT
SPECT with ultra-high energy collimators for
511 KeV acquisition has emerged as an alternative to PET
for the assessment of myocardial viability.82 Despite the
limited spatial resolution and counting sensitivity of
SPECT compared to PET, several clinical studies have
shown that 18F-FDG SPECT offers diagnostic information similar to PET, and compares favorably with other
imaging modalities, including rest-redistribution,83 stressreinjection 201Tl imaging,84 or low dose dobutamine
echocardiography.84 As with PET studies, metabolic activity measured by 18F-FDG SPECT is interpreted in
combination with flow tracer. For this purpose, a dualisotope simultaneous acquisition (DISA) protocol with
18F-FDG and 99mTc-perfusion tracer is attractive because
it enables assessment of myocardial glucose utilization
and perfusion in a single study85–87 (Fig. 4). Another
potential advantage of this protocol is that ECG-gating to
assess left ventricular function is feasible. Thus, DISA
SPECT has the potential to assess myocardial glucose
utilization, perfusion, and function in a single study.
18F-FDG
99mTc-Labeled
Flow Tracers
Technetium-99m labeled flow tracers such as 99mTcsestamibi and 99mTc-tetrofosmin are now widely available as alternatives to conventional 201Tl. As compared
with 201Tl, these 99mTc-labeled agents yield higher image
quality, but the diagnostic performance of these tracers
for detection of CAD is offset by underestimation of flow
at high flow rates.68,69 A more important characteristic
of these tracers is that, unlike 201Tl, they do not show
significant redistribution over time, and therefore there
have been controversies regarding the use of 99mTclabeled agents as a viability tracer.70 In experimental
studies, however, myocardial retention of both 99mTcsestamibi and 99mTc-tetrofosmin requires cellular viability as demonstrated by Takahashi et al.71 Perhaps due to
the lack of redistribution and underestimation of flow at
high flow rates, both stress-rest 99mTc-sestamibi and 99mTctetrofosmin underestimate defect reversibility as compared with stress-reinjection 201Tl.72,73 However, regional
99mTc-sestamibi18 or 99mTc-tetrofosmin20 activity closely
correlates with that of 201Tl as illustrated in Figure 2,
indicating that quantitation of tracer uptake may be used
Vol. 17, No. 3, 2003
Review 173
Fig. 5 99mTc-sestamibi (upper) and 18F-FDG SPECT (lower)
images acquired simultaneously from a patient with inferior
myocardial infarction. A reduced perfusion associated with
preserved 18F-FDG uptake (flow-metabolism mismatch) is noted.
Fig. 4 The non-attenuation corrected (NC) 99mTc-tetrofosmin
images (left), attenuation corrected (AC) 99mTc-tetrofosmin
images (center) and positron emission tomography with 18FFDG (right) from a patient with 3-vessel coronary artery disease. (From Matsunari I, Böning G, Ziegler SI, et al. Attenuation-corrected 99mTc-tetrofosmin single-photon emission
computed tomography in the detection of viable myocardium:
comparison with positron emission tomography using 18Ffluorodeoxyglucose. J Am Coll Cardiol 1998; 32: 927–935.
Reproduced with permission of the American College of Cardiology.)
Recent Methodological Developments in SPECT Viability Studies
Nitrates
The use of nitrates at the time of tracer injection reportedly
enhances the diagnostic accuracy of viability tests using
flow tracers, as evidenced by several studies.88–90 In
particular, Sciagra et al.91 have found that nitrate induced
changes in 99mTc-sestamibi activity are an accurate marker
of potentially reversible myocardium, which was true for
both regional91 and global92 functional recovery. Furthermore, the prognostic value of nitrate enhanced 99mTcsestamibi imaging has been validated in another study by
this group.93 Thus, baseline-nitrate perfusion imaging
appears to be an attractive approach for assessing tissue
viability. One disadvantage of this protocol is the necessity for two separate injections of the tracer, relatively
long time required for completion of the imaging procedure.
Attenuation Correction
It is well known that attenuation artifacts may unfavorably affect the diagnostic accuracy of cardiac SPECT
imaging. In particular, patients with severe left ventricular dysfunction, in whom the extent of viable myocardium
becomes an important issue for clinical decision making,
are likely to have an enlarged left ventricle, and are susceptible to diaphragmatic attenuation artifacts. Therefore,
the use of attenuation correction would improve the
174
Ichiro Matsunari, Junichi Taki, Kenichi Nakajima, et al
accuracy of viability tests using SPECT techniques. This
hypothesis was confirmed by a recent study demonstrating that the use of attenuation correction significantly
improved the detection of viable myocardium by decreasing false negatives in the inferior-septal region using 18FFDG PET as a reference technique for tissue viability,94
although this needs to be further validated in patients
undergoing revascularization.
Gated-SPECT
Recent developments in 99mTc-labeled myocardial perfusion tracers and data processing95 have made ECG-gated
SPECT imaging part of the clinical routine in nuclear
imaging laboratories. Gated-SPECT may enhance the
diagnostic accuracy of the viability test by increasing
specificity.96,97 In particular, dobutamine stress gated
SPECT using 99mTc-labeled flow tracer provides information on both perfusion and contractile reserve in a
single study as recently documented by Yoshinaga et
al.,98 who compared the accuracy of low-dose dobutamine
stress gated myocardial SPECT with the accuracy of
dobutamine stress echocardiography and resting perfusion SPECT for the identification of viable myocardium
in patients with previous myocardial infarction. Because
SPECT is more objective and reproducible than echocardiography, gated-SPECT with pharmacological intervention may become an indispensable diagnostic tool
for viability testing.
Non-Nuclear Imaging Techniques
There are several non-nuclear imaging techniques that
can be used for the detection of viable tissue. Each of them
has its own advantages and disadvantages as compared
with nuclear imaging.
Echocardiography
Contractile reserve assessed by low-dose dobutamine
echocardiography is a currently well accepted marker of
tissue viability.67,99–102 When the results of dobutamine
Annals of Nuclear Medicine
echocardiography are compared with those of nuclear
imaging, echocardiography generally has higher specificity
but somewhat lower sensitivity as compared with 201Tl
imaging.103
imaging as a reliable, indispensable viability test for
clinical decision making.
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is another potent
diagnostic tool for myocardial viability assessment. It can
assess contractile reserve as does dobutamine echocardiography in a more objective manner.15 Furthermore,
delayed enhancement using contrast media seems to be
a reliable marker for scar tissue as compared with 201Tl
imaging104 or PET.105 At present, however, clinical experience with MRI is limited, and therefore clinical
trials especially involving patients undergoing revascularization need to be done before its utility is determined.
1. Bonow RO. Identification of viable myocardium. Circulation 1996; 94: 2674–2680.
2. Haas F, Haehnel CJ, Picker W, Nekolla S, Martinoff S,
Meisner H, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997; 30: 1693–1700.
3. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern
M, Phelps M, et al. Reversibility of cardiac wall-motion
abnormalities predicted by positron tomography. N Engl J
Med 1986; 314: 884–888.
4. Tamaki N, Yonekura Y, Yamashita K, Magata Y, Senda M,
Konishi Y, et al. Positron emission tomography using
fluorine-18 deoxyglucose in evaluation of coronary artery
bypass grafting. Am J Cardiol 1989; 64: 860–865.
5. Ragosta M, Beller GA, Watson DD, Kaul S, Gimple LW.
Quantitative planar rest-redistribution 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass
surgery in patients with severely depressed left ventricular
function. Circulation 1993; 87: 1630–1641.
6. Dilsizian V, Rocco TP, Freedman NM, Leon MB, Bonow
RO. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990; 323: 141–146.
7. Rahimtoola SH. The hibernating myocardium. Am Heart J
1989; 117: 211–221.
8. Dilsizian V, Bonow RO. Current diagnostic techniques of
assessing myocardial viability in patients with hibernating
and stunned myocardium. Circulation 1993; 87: 1–20.
9. Gerber BL, Vanoverschelde JL, Bol A, Michel C, Labar D,
Wijns W, et al. Myocardial blood flow, glucose uptake, and
recruitment of inotropic reserve in chronic left ventricular
ischemic dysfunction. Implications for the pathophysiology of chronic myocardial hibernation. Circulation 1996;
94: 651–659.
10. Sun KT, Czernin J, Krivokapich J, Lau YK, Bottcher M,
Maurer G, et al. Effects of dobutamine stimulation on
myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium. Circulation
1996; 94: 3146–3154.
11. Bax JJ, Visser FC, Poldermans D, Elhendy A, Cornel JH,
Boersma E, et al. Time course of functional recovery of
stunned and hibernating segments after surgical revascularization. Circulation 2001; 104: I314–I318.
12. Haas F, Augustin N, Holper K, Wottke M, Haehnel C,
Nekolla S, et al. Time course and extent of improvement of
dysfunctioning myocardium in patients with coronary artery disease and severely depressed left ventricular function
after revascularization: correlation with positron emission
tomographic findings. J Am Coll Cardiol 2000; 36: 1927–
1934.
13. Sawada S, Elsner G, Segar DS, O’Shaughnessy M, Khouri
S, Foltz J, et al. Evaluation of patterns of perfusion and
metabolism in dobutamine-responsive myocardium. J Am
Sequential Strategy Using Multi-Modalities
Although one imaging technique has advantages and
disadvantages over other techniques as described earlier,
this can be improved by combining two or more imaging
modalities. This concept was recently tested in a study by
Bax et al.106 demonstrating that the combination of 201Tl
and dobutamine echocardiography in a subset of patients
significantly improved overall accuracy of the test, suggesting that these diagnostic techniques may work in a
complementary fashion. It should be noted that the sequential strategy requires two or more diagnostic tests
performed in patients, and therefore is more expensive
than performing one test alone. Therefore, the question to
be addressed in further studies is whether the additional
costs imposed by the sequential test are offset by the
improved diagnostic accuracy.107
CONCLUSION
Accurate assessment of myocardial viability continues to
be an important issue for clinical decision making in
patients with CAD and left ventricular dysfunction. Nuclear
imaging using either SPECT or PET has played a major
role for identification of such viable myocardium as
described in this review. Recently, however, other imaging techniques such as dobutamine echocardiography
have emerged as competitors to nuclear imaging. It is
noteworthy that they sometimes may work in a complementary fashion to nuclear imaging, indicating that an
appropriate use of these techniques may significantly
improve the overall accuracy. On the other hand, reimbursement for cardiac metabolic imaging using 18F-FDG
PET has recently been approved by the Ministry of
Health, Labour and Welfare in Japan, which would promote more wide-spread use of PET imaging in clinical
practice. Thus, the circumstances surrounding nuclear
imaging as a viability test are changing dynamically.
Keeping these factors in mind, more efforts are necessary
to further enhance the diagnostic performance of nuclear
Vol. 17, No. 3, 2003
REFERENCES
Review 175
Coll Cardiol 1997; 29: 55–61.
14. Elsasser A, Schlepper M, Klovekorn WP, Cai WJ,
Zimmermann R, Muller KD, et al. Hibernating myocardium: an incomplete adaptation to ischemia. Circulation
1997; 96: 2920–2931.
15. Baer FM, Voth E, Schneider CA, Theissen P, Schicha H,
Sechtem U. Comparison of low-dose dobutamine-gradientecho magnetic resonance imaging and positron emission
tomography with [18F]fluorodeoxyglucose in patients with
chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial
viability. Circulation 1995; 91: 1006–1015.
16. Zimmermann R, Mall G, Rauch B, Zimmer G, Gabel M,
Zehelein J, et al. Residual 201Tl activity in irreversible
defects as a marker of myocardial viability. Clinicopathological study. Circulation 1995; 91: 1016–1021.
17. vom-Dahl J, Eitzman DT, Al-Aouar ZR, Kanter HL, Hicks
RJ, Deeb GM, et al. Relation of regional function, perfusion, and metabolism in patients with advanced coronary
artery disease undergoing surgical revascularization. Circulation 1994; 90: 2356–2366.
18. Udelson JE, Coleman PS, Metherall J, Pandian NG, Gomez
AR, Griffith JL, et al. Predicting recovery of severe regional
ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. Circulation 1994; 89:
2552–2561.
19. Tamaki N, Kawamoto M, Tadamura E, Magata Y, Yonekura
Y, Nohara R, et al. Prediction of reversible ischemia after
revascularization. Perfusion and metabolic studies with
positron emission tomography. Circulation 1995; 91: 1697–
1705.
20. Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi
T, et al. Quantitative rest technetium-99m tetrofosmin imaging in predicting functional recovery after revascularization: comparison with rest-redistribution thallium-201. J
Am Coll Cardiol 1997; 29: 1226–1233.
21. Di Carli MF, Asgarzadie F, Schelbert HR, Brunken RC,
Laks H, Phelps ME, et al. Quantitative relation between
myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995; 92: 3436–3444.
22. Bax JJ, Poldermans D, Elhendy A, Cornel JH, Boersma E,
Rambaldi R, et al. Improvement of left ventricular ejection
fraction, heart failure symptoms and prognosis after
revascularization in patients with chronic coronary artery
disease and viable myocardium detected by dobutamine
stress echocardiography. J Am Coll Cardiol 1999; 34: 163–
169.
23. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV,
Brunken RC, et al. Value of metabolic imaging with positron
emission tomography for evaluating prognosis in patients
with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994; 73: 527–533.
24. Cuocolo A, Petretta M, Nicolai E, Pace L, Bonaduce D,
Salvatore M, et al. Successful coronary revascularization
improves prognosis in patients with previous myocardial
infarction and evidence of viable myocardium at thallium201 imaging. Eur J Nucl Med 1998; 25: 60–68.
25. Tamaki N, Kawamoto M, Takahashi N, Yonekura Y, Magata
Y, Nohara R, et al. Prognostic value of an increase in
fluorine-18 deoxyglucose uptake in patients with myocar-
176
Ichiro Matsunari, Junichi Taki, Kenichi Nakajima, et al
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
dial infarction: comparison with stress thallium imaging. J
Am Coll Cardiol 1993; 22: 1621–1627.
Opie LH. Metabolism of the heart in health and disease. I.
Am Heart J 1968; 76: 685–698.
Opie LH. Metabolism of the heart in health and disease. 3.
Am Heart J 1969; 77: 383–410.
Opie LH. Metabolism of the heart in health and disease. II.
Am Heart J 1969; 77: 100–122 contd.
Opie LH. Effects of regional ischemia on metabolism of
glucose and fatty acids. Relative rates of aerobic and anaerobic energy production during myocardial infarction and
comparison with effects of anoxia. Circ Res 1976; 38: I52–
I74.
Camici P, Ferrannini E, Opie LH. Myocardial metabolism
in ischemic heart disease: basic principles and application
to imaging by positron emission tomography. Prog
Cardiovasc Dis 1989; 32: 217–238.
King LM, Opie LH. Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with
a residual coronary flow. Cardiovasc Res 1998; 39: 381–
392.
Baer FM, Voth E, Deutsch HJ, Schneider CA, Horst M, de
Vivie ER, et al. Predictive value of low dose dobutamine
transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery
of regional left ventricular function after successful revascularization. J Am Coll Cardiol 1996; 28: 60–69.
Haas F, Jennen L, Heinzmann U, Augustin N, Wottke M,
Schwaiger M, et al. Ischemically compromised myocardium displays different time-courses of functional recovery: correlation with morphological alterations? Eur J
Cardiothorac Surg 2001; 20: 290–298.
Knuuti MJ, Nuutila P, Ruotsalainen U, Teras M, Saraste M,
Harkonen R, et al. The value of quantitative analysis of
glucose utilization in detection of myocardial viability by
PET. J Nucl Med 1993; 34: 2068–2075.
Sebree L, Bianco JA, Subramanian R, Wilson MA, Swanson
D, Hegge J, et al. Discordance between accumulation of
C-14 deoxyglucose and Tl-201 in reperfused myocardium.
J Mol Cell Cardiol 1991; 23: 603–616.
Hashimoto K, Uehara T, Ishida Y, Nonogi H, Kusuoka H,
Nishimura T. Paradoxical uptake of F-18 fluorodeoxyglucose
by successfully reperfused myocardium during the subacute phase in patients with acute myocardial infarction.
Ann Nucl Med 1996; 10: 93–98.
Nonogi H, Miyazaki S, Goto Y, Ishida Y, Uehara T,
Nishimura T. Efficacy and limitation of F-18-fluorodeoxyglucose positron emission tomography during fasting to
assess myocardial viability in the acute phase of myocardial
infarction. Intern Med 1998; 37: 653–661.
Gropler RJ, Geltman EM, Sampathkumaran K, Perez JE,
Moerlein SM, Sobel BE, et al. Functional recovery after
coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism.
J Am Coll Cardiol 1992; 20: 569–577.
Gropler RJ, Siegel BA, Sampathkumaran K, Perez JE,
Sobel BE, Bergmann SR, et al. Dependence of recovery of
contractile function on maintenance of oxidative metabolism after myocardial infarction. J Am Coll Cardiol 1992;
19: 989–997.
Gropler RJ, Geltman EM, Sampathkumaran K, Perez JE,
Annals of Nuclear Medicine
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
Schechtman KB, Conversano A, et al. Comparison of
carbon-11-acetate with fluorine-18-fluorodeoxyglucose for
delineating viable myocardium by positron emission tomography. J Am Coll Cardiol 1993; 22: 1587–1597.
Rubin PJ, Lee DS, Davila-Roman VG, Geltman EM,
Schechtman KB, Bergmann SR, et al. Superiority of C-11
acetate compared with F-18 fluorodeoxyglucose in predicting myocardial functional recovery by positron emission
tomography in patients with acute myocardial infarction.
Am J Cardiol 1996; 78: 1230–1235.
Hata T, Nohara R, Fujita M, Hosokawa R, Lee L, Kudo T,
et al. Noninvasive assessment of myocardial viability by
positron emission tomography with 11C acetate in patients
with old myocardial infarction. Usefulness of low-dose
dobutamine infusion. Circulation 1996; 94: 1834–1841.
Wolpers HG, Burchert W, van den Hoff J, Weinhardt R,
Meyer GJ, Lichtlen PR. Assessment of myocardial viability
by use of 11C-acetate and positron emission tomography.
Threshold criteria of reversible dysfunction. Circulation
1997; 95: 1417–1424.
Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich
J, Schelbert H, Kuhl DE. Noninvasive quantification of
regional blood flow in the human heart using N-13 ammonia
and dynamic positron emission tomographic imaging. J Am
Coll Cardiol 1990; 15: 1032–1042.
Iida H, Kanno I, Takahashi A, Miura S, Murakami M,
Takahashi K, et al. Measurement of absolute myocardial
blood flow with H215O and dynamic positron-emission
tomography. Strategy for quantification in relation to the
partial-volume effect. Circulation 1988; 78: 104–115.
Endo M, Yoshida K, Iinuma TA, Yamasaki T, Tateno Y,
Masuda Y, et al. Noninvasive quantification of regional
myocardial blood flow and ammonia extraction fraction
using nitrogen-13 ammonia and positron emission tomography. Ann Nucl Med 1987; 1: 1–6.
Nagamachi S, Czernin J, Kim AS, Sun KT, Bottcher M,
Phelps ME, et al. Reproducibility of measurements of
regional resting and hyperemic myocardial blood flow
assessed with PET. J Nucl Med 1996; 37: 1626–1631.
Tadamura E, Tamaki N, Yonekura Y, Kudoh T, Magata Y,
Torizuka T, et al. Assessment of coronary vasodilator
reserve by N-13 ammonia PET using the microsphere
method and Patlak plot analysis. Ann Nucl Med 1995; 9:
109–118.
Muzik O, Beanlands RS, Hutchins GD, Mangner TJ, Nguyen
N, Schwaiger M. Validation of nitrogen-13-ammonia tracer
kinetic model for quantification of myocardial blood flow
using PET. J Nucl Med 1993; 34: 83–91.
Chen BC, Germano G, Huang SC, Hawkins RA, Hansen
HW, Robert MJ, et al. A new noninvasive quantification of
renal blood flow with N-13 ammonia, dynamic positron
emission tomography, and a two-compartment model. J Am
Soc Nephrol 1992; 3: 1295–1306.
Krivokapich J, Stevenson LW, Kobashigawa J, Huang SC,
Schelbert HR. Quantification of absolute myocardial perfusion at rest and during exercise with positron emission
tomography after human cardiac transplantation. J Am Coll
Cardiol 1991; 18: 512–517.
Krivokapich J, Smith GT, Huang SC, Hoffman EJ, Ratib O,
Phelps ME, et al. 13N ammonia myocardial imaging at rest
and with exercise in normal volunteers. Quantification of
Vol. 17, No. 3, 2003
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
absolute myocardial perfusion with dynamic positron emission tomography. Circulation 1989; 80: 1328–1337.
Kitsiou AN, Bacharach SL, Bartlett ML, Srinivasan G,
Summers RM, Quyyumi AA, et al. 13N-ammonia myocardial blood flow and uptake: relation to functional outcome
of asynergic regions after revascularization. J Am Coll
Cardiol 1999; 33: 678–686.
Duvernoy CS, vom Dahl J, Laubenbacher C, Schwaiger M.
The role of nitrogen 13 ammonia positron emission tomography in predicting functional outcome after coronary
revascularization. J Nucl Cardiol 1995; 2: 499–506.
Huang SC, Schwaiger M, Carson RE, Carson J, Hansen H,
Selin C, et al. Quantitative measurement of myocardial
blood flow with oxygen-15 water and positron computed
tomography: an assessment of potential and problems. J
Nucl Med 1985; 26: 616–625.
Nitzsche EU, Choi Y, Czernin J, Hoh CK, Huang SC,
Schelbert HR. Noninvasive quantification of myocardial
blood flow in humans. A direct comparison of the
[13N]ammonia and the [15O]water techniques. Circulation
1996; 93: 2000–2006.
Yamamoto Y, de Silva R, Rhodes CG, Araujo LI, Iida H,
Rechavia E, et al. A new strategy for the assessment of
viable myocardium and regional myocardial blood flow
using 15O-water and dynamic positron emission tomography. Circulation 1992; 86: 167–178.
de Silva R, Yamamoto Y, Rhodes CG, Iida H,
Nihoyannopoulos P, Davies GJ, et al. Preoperative prediction of the outcome of coronary revascularization using
positron emission tomography. Circulation 1992; 86: 1738–
1742.
vom Dahl J, Muzik O, Wolfe ER Jr, Allman C, Hutchins G,
Schwaiger M. Myocardial rubidium-82 tissue kinetics assessed by dynamic positron emission tomography as a
marker of myocardial cell membrane integrity and viability.
Circulation 1996; 93: 238–245.
Leppo JA. Myocardial uptake of thallium and rubidium
during alterations in perfusion and oxygenation in isolated
rabbit hearts. J Nucl Med 1987; 28: 878–885.
Brunken RC, Mody FV, Hawkins RA, Nienaber C, Phelps
ME, Schelbert HR. Positron emission tomography detects
metabolic viability in myocardium with persistent 24-hour
single-photon emission computed tomography 201Tl defects. Circulation 1992; 86: 1357–1369.
Kiat H, Berman DS, Maddahi J, De Yang L, Van Train K,
Rozanski A, et al. Late reversibility of tomographic myocardial thallium-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol 1988; 12: 1456–1463.
Taki J, Nakajima K, Bunko H, Kawasuji M, Tonami N,
Hisada K. Twenty-four-hour quantitative thallium imaging
for predicting beneficial revascularization. Eur J Nucl Med
1994; 21: 1212–1217.
Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL.
Identification of viable myocardium in patients with chronic
coronary artery disease and left ventricular dysfunction.
Comparison of thallium scintigraphy with reinjection and
PET imaging with 18F-fluorodeoxyglucose. Circulation
1991; 83: 26–37.
Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi
T, et al. Significance of late redistribution thallium-201
imaging after rest injection for detection of viable myocar-
Review 177
dium. J Nucl Med 1997; 38: 1073–1078.
66. Kitsiou AN, Srinivasan G, Quyyumi AA, Summers RM,
Bacharach SL, Dilsizian V. Stress-induced reversible and
mild-to-moderate irreversible thallium defects: are they
equally accurate for predicting recovery of regional left
ventricular function after revascularization? Circulation
1998; 98: 501–508.
67. Qureshi U, Nagueh SF, Afridi I, Vaduganathan P, Blaustein
A, Verani MS, et al. Dobutamine echocardiography and
quantitative rest-redistribution 201Tl tomography in myocardial hibernation. Relation of contractile reserve to 201Tl
uptake and comparative prediction of recovery of function.
Circulation 1997; 95: 626–635.
68. Glover DK, Ruiz M, Koplan BA, Watson DD, Beller GA.
99mTc-tetrofosmin assessment of myocardial perfusion and
viability in canine models of coronary occlusion and
reperfusion. J Nucl Med 1999; 40: 142–149.
69. Glover DK, Ruiz M, Edwards NC, Cunningham M, Simanis
JP, Smith WH, et al. Comparison between 201Tl and 99mTc
sestamibi uptake during adenosine-induced vasodilation as
a function of coronary stenosis severity. Circulation 1995;
91: 813–820.
70. Marzullo P, Parodi O, Reisenhofer B, Sambuceti G, Picano
E, Distante A, et al. Value of rest thallium-201/technetium99m sestamibi scans and dobutamine echocardiography for
detecting myocardial viability. Am J Cardiol 1993; 71:
166–172.
71. Takahashi N, Reinhardt CP, Marcel R, Leppo JA. Myocardial uptake of 99mTc-tetrofosmin, sestamibi, and 201Tl in a
model of acute coronary reperfusion. Circulation 1996; 94:
2605–2613.
72. Cuocolo A, Pace L, Ricciardelli B, Chiariello M, Trimarco
B, Salvatore M. Identification of viable myocardium in
patients with chronic coronary artery disease: comparison
of thallium-201 scintigraphy with reinjection and technetium-99m-methoxyisobutyl isonitrile. J Nucl Med 1992;
33: 505–511.
73. Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi
T, et al. Myocardial viability assessment with technetium99m-tetrofosmin and thallium-201 reinjection in coronary
artery disease. J Nucl Med 1995; 36: 1961–1967.
74. Acampa W, Cuocolo A, Petretta M, Bruno A, Castellani M,
Finzi A, et al. Tetrofosmin imaging in the detection of
myocardial viability in patients with previous myocardial
infarction: comparison with sestamibi and Tl-201 scintigraphy. J Nucl Cardiol 2002; 9: 33–40.
75. Cuocolo A, Acampa W, Nicolai E, Pace L, Petretta M,
Salvatore M. Quantitative thallium-201 and technetium
99m sestamibi tomography at rest in detection of myocardial viability in patients with chronic ischemic left ventricular dysfunction. J Nucl Cardiol 2000; 7: 8–15.
76. Knapp F Jr, Kropp J. BMIPP-design and development. Int
J Card Imaging 1999; 15: 1–9.
77. Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi
T, et al. Impaired fatty acid uptake in ischemic but viable
myocardium identified by thallium-201 reinjection. Am
Heart J 1996; 131: 458–465.
78. Taki J, Nakajima K, Matsunari I, Bunko H, Takata S,
Kawasuji M, et al. Assessment of improvement of myocardial fatty acid uptake and function after revascularization
using iodine-123-BMIPP. J Nucl Med 1997; 38: 1503–
178
Ichiro Matsunari, Junichi Taki, Kenichi Nakajima, et al
1510.
79. Hambye AS, Vaerenberg MM, Dobbeleir AA, Van den
Heuvel PA, Franken PR. Abnormal BMIPP uptake in
chronically dysfunctional myocardial segments: correlation with contractile response to low-dose dobutamine. J
Nucl Med 1998; 39: 1845–1850.
80. Franken PR, Hambye AS, De Geeter FW. BMIPP imaging
to assess functional outcome in patients with acute and
chronic left ventricular dysfunction. Int J Card Imaging
1999; 15: 27–34.
81. Hambye AS, Dobbeleir AA, Vervaet AM, Van den Heuvel
PA, Franken PR. BMIPP imaging to improve the value of
sestamibi scintigraphy for predicting functional outcome in
severe chronic ischemic left ventricular dysfunction. J Nucl
Med 1999; 40: 1468–1476.
82. Bax JJ, Visser FC, van Lingen A, Huitink JM, Kamp O, van
Leeuwen GR, et al. Feasibility of assessing regional myocardial uptake of 18F-fluorodeoxyglucose using single photon emission computed tomography. Eur Heart J 1993; 14:
1675–1682.
83. Bax JJ, Cornel JH, Visser FC, Fioretti PM, van Lingen A,
Huitink JM, et al. Comparison of fluorine-18-FDG with
rest-redistribution thallium-201 SPECT to delineate viable
myocardium and predict functional recovery after revascularization. J Nucl Med 1998; 39: 1481–1486.
84. Bax JJ, Cornel JH, Visser FC, Fioretti PM, van Lingen A,
Reijs AE, et al. Prediction of recovery of myocardial dysfunction after revascularization. Comparison of fluorine-18
fluorodeoxyglucose/thallium-201 SPECT, thallium-201
stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol 1996; 28: 558–564.
85. Sandler MP, Videlefsky S, Delbeke D, Patton JA,
Meyerowitz C, Martin WH, et al. Evaluation of myocardial
ischemia using a rest metabolism/stress perfusion protocol
with fluorine-18 deoxyglucose/technetium-99m MIBI and
dual-isotope simultaneous-acquisition single-photon emission computed tomography. J Am Coll Cardiol 1995; 26:
870–878.
86. Fukuchi K, Katafuchi T, Fukushima K, Shimotsu Y, Toba
M, Hayashida K, et al. Estimation of myocardial perfusion
and viability using simultaneous 99mTc-tetrofosmin—FDG
collimated SPECT. J Nucl Med 2000; 41: 1318–1323.
87. Matsunari I, Kanayama S, Yoneyama T, Matsudaira M,
Nakajima K, Taki J, et al. Myocardial distribution of 18FFDG and 99mTc-sestamibi on dual-isotope simultaneous
acquisition SPET compared with PET. Eur J Nucl Med Mol
Imaging 2002; 29: 1357–1364.
88. Toyama T, Hoshizaki H, Isobe N, Adachi H, Naito S,
Oshima S, et al. Detecting viable hibernating myocardium
in chronic coronary artery disease—a comparison of resting
201 Tl single photon emission computed tomography
(SPECT), 99mTc-methoxy-isobutyl isonitrile SPECT after
nitrate administration, and 201Tl SPECT after 201Tl-glucose-insulin infusion. Jpn Circ J 2000; 64: 937–942.
89. Sciagra R, Bisi G, Santoro GM, Agnolucci M, Zoccarato O,
Fazzini PF. Influence of the assessment of defect severity
and intravenous nitrate administration during tracer injection on the detection of viable hibernating myocardium with
data-based quantitative technetium 99m-labeled sestamibi
single-photon emission computed tomography. J Nucl
Cardiol 1996; 3: 221–230.
Annals of Nuclear Medicine
90. He ZX, Medrano R, Hays JT, Mahmarian JJ, Verani MS.
Nitroglycerin-augmented 201Tl reinjection enhances detection of reversible myocardial hypoperfusion. A randomized, double-blind, parallel, placebo-controlled trial. Circulation 1997; 95: 1799–1805.
91. Sciagra R, Bisi G, Santoro GM, Zerauschek F, Sestini S,
Pedenovi P, et al. Comparison of baseline-nitrate technetium-99m sestamibi with rest-redistribution thallium-201
tomography in detecting viable hibernating myocardium
and predicting postrevascularization recovery. J Am Coll
Cardiol 1997; 30: 384–391.
92. Sciagra R, Leoncini M, Marcucci G, Dabizzi RP, Pupi A.
Technetium-99m sestamibi imaging to predict left ventricular ejection fraction outcome after revascularisation in
patients with chronic coronary artery disease and left
ventricular dysfunction: comparison between baseline and
nitrate-enhanced imaging. Eur J Nucl Med 2001; 28: 680–
687.
93. Sciagra R, Pellegri M, Pupi A, Bolognese L, Bisi G,
Carnovale V, et al. Prognostic implications of Tc-99m
sestamibi viability imaging and subsequent therapeutic
strategy in patients with chronic coronary artery disease and
left ventricular dysfunction. J Am Coll Cardiol 2000; 36:
739–745.
94. Matsunari I, Boning G, Ziegler SI, Nekolla SG, Stollfuss
JC, Kosa I, et al. Attenuation-corrected 99mTc-tetrofosmin
single-photon emission computed tomography in the detection of viable myocardium: comparison with positron emission tomography using 18F-fluorodeoxyglucose. J Am Coll
Cardiol 1998; 32: 927–935.
95. Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M,
Su HT, et al. Automatic quantification of ejection fraction
from gated myocardial perfusion SPECT. J Nucl Med 1995;
36: 2138–2147.
96. Stollfuss JC, Haas F, Matsunari I, Neverve J, Nekolla S,
Ziegler S, et al. 99mTc-tetrofosmin SPECT for prediction of
functional recovery defined by MRI in patients with severe
left ventricular dysfunction: additional value of gated
SPECT. J Nucl Med 1999; 40: 1824–1831.
97. Kuwabara Y, Watanabe S, Nakaya J, Fujiwara M, Hasegawa
R, Matsuno K, et al. Functional evaluation of myocardial
viability by 99mTc tetrofosmin gated SPECT—a quantitative comparison with 18F fluorodeoxyglucose positron emission CT (18F FDG PET). Ann Nucl Med 1999; 13: 135–140.
98. Yoshinaga K, Morita K, Yamada S, Komuro K, Katoh C, Ito
Y, et al. Low-dose dobutamine electrocardiograph-gated
myocardial SPECT for identifying viable myocardium:
Vol. 17, No. 3, 2003
99.
100.
101.
102.
103.
104.
105.
106.
107.
comparison with dobutamine stress echocardiography and
PET. J Nucl Med 2001; 42: 838–844.
Smart SC. The clinical utility of echocardiography in the
assessment of myocardial viability. J Nucl Med 1994; 35:
49S–58S.
Arnese M, Cornel JH, Salustri A, Maat A, Elhendy A, Reijs
AE, et al. Prediction of improvement of regional left
ventricular function after surgical revascularization. A
comparison of low-dose dobutamine echocardiography
with 201Tl single-photon emission computed tomography.
Circulation 1995; 91: 2748–2752.
Baumgartner H, Porenta G, Lau YK, Wutte M, Klaar U,
Mehrabi M, et al. Assessment of myocardial viability by
dobutamine echocardiography, positron emission tomography and thallium-201 SPECT: correlation with histopathology in explanted hearts. J Am Coll Cardiol 1998; 32:
1701–1708.
Barilla F, De Vincentis G, Mangieri E, Ciavolella M,
Panitteri G, Scopinaro F, et al. Recovery of contractility of
viable myocardium during inotropic stimulation is not
dependent on an increase of myocardial blood flow in the
absence of collateral filling. J Am Coll Cardiol 1999; 33:
697–704.
Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E,
Fioretti PM. Accuracy of currently available techniques
for prediction of functional recovery after revascularization
in patients with left ventricular dysfunction due to chronic
coronary artery disease: comparison of pooled data. J Am
Coll Cardiol 1997; 30: 1451–1460.
Ramani K, Judd RM, Holly TA, Parrish TB, Rigolin VH,
Parker MA, et al. Contrast magnetic resonance imaging in
the assessment of myocardial viability in patients with
stable coronary artery disease and left ventricular dysfunction. Circulation 1998; 98: 2687–2694.
Klein C, Nekolla SG, Bengel FM, Momose M, Sammer A,
Haas F, et al. Assessment of myocardial viability with
contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 2002;
105: 162–167.
Bax JJ, Maddahi J, Poldermans D, Elhendy A, Cornel JH,
Boersma E, et al. Sequential 201Tl imaging and dobutamine echocardiography to enhance accuracy of predicting improved left ventricular ejection fraction after
revascularization. J Nucl Med 2002; 43: 795–802.
Matsunari I, Taki J, Tonami N. Sequential strategy using
multimodality viability tests: does it work? [invited commentary] J Nucl Med 2002; 43: 803–805.
Review 179